Skip to main content
Log in

Primärer Hyperaldosteronismus: Diagnostik und Therapie

Primary aldosteronism: diagnosis and therapy

  • Originalien
  • Published:
Journal für Klinische Endokrinologie und Stoffwechsel Aims and scope

Zusammenfassung

Der primäre Hyperaldosteronismus (PHA) ist die häufigste sekundäre Hypertonieform mit einer Prävalenz von ca. 5 % bei Patienten mit arteriellem Hypertonus. Die Erkrankung ist charakterisiert durch eine inadäquat hohe Aldosteronsekretion in einer oder beiden Nebennieren. Abklärung und Therapie des PHA sind indiziert, weil Patienten mit PHA im Vergleich zu Patienten mit essentiellem arteriellen Hypertonus, auch bei gleichen Blutdruckwerten, ein signifikant erhöhtes kardiovaskuläres Risiko aufweisen und der PHA sehr gut durch eine spezifische Therapie behandelbar ist.

In den Richtlinien der Endocrine Society wird daher ein weitreichendes Screening auf PHA bei Hypertonikern empfohlen. Als Screeningtest wird die Bestimmung der Aldosteron-zu-Renin-Ratio (ARR) empfohlen, wobei nach einer erhöhten ARR meistens ein Bestätigungstest (z. B. i. v. Kochsalzbelastungstest) angeschlossen werden sollte. Bei biochemischem Nachweis eines PHA wird anschließend evaluiert, ob es sich um eine einseitige (Aldosteron produzierendes Adenom) oder eine beidseitige Aldosteronhypersekretion (bilaterale Nebennierenhyperplasie) handelt, denn die einseitige Erkrankung wird operativ, die beidseitige medikamentös z. B. mit Mineralokortikoidrezeptorblockern behandelt. Die Richtlinien empfehlen zur Unterscheidung neben einem Nebennieren-CT ein so genanntes adrenales Venensampling (AVS), d. h. Blutabnahme und Hormonbestimmungen aus der rechten und linken Nebennierenvene. Neuere Studiendaten legen jedoch nahe, dass eine rein auf dem CT-Befund basierende Subtypenklassifizierung bzw. Therapie dem AVS basierten Vorgehen ebenbürtig ist.

Obwohl die Leitlinien bei in etwa jedem 2. Patienten mit arteriellem Hypertonus eine Abklärung auf PHA empfehlen, wird dies in der allgemeinen Praxis derzeit kaum umgesetzt, weswegen nach wie vor die meisten Patienten mit PHA nicht diagnostiziert und somit auch oft untherapiert sind.

Abstract

Primary aldosteronism (PA) is the most common cause of endocrine hypertension with an estimated prevalence of 5% among patients with arterial hypertension. PA is characterized by inadequately high aldosterone secretion from one or both adrenal glands. Diagnosis and therapy of PA is indicated because patients with PA have, compared to patients with essential arterial hypertension, even at the same blood pressure, a significantly higher cardiovascular risk, that can be effectively treated by specific therapy.

Therefore, the Endocrine Society guidelines recommend broad screening for PA among hypertensive patients. The determination of the aldosterone-to-renin ratio (ARR) is the recommended screening test for PA. In the case of an elevated ARR, a confirmatory test (e. g. i. v. saline infusion test), should be performed. If PA is biochemically confirmed, subtype classification, i. e. differentiation between unilateral (aldosterone producing adenoma) and bilateral aldosterone hypersecretion (bilateral adrenal hyperplasia), is important because unilateral diseases can be treated by adrenal surgery whereas bilateral diseases are treated by drugs, e. g. mineralocorticoid receptor blockers. In addition to an adrenal computed tomography (CT), guidelines recommend adrenal venous sampling (i. e. blood collection for hormone measurement from the right and left adrenal vein) for subtype determination. Recent study results, however, suggest that CT based subtype classification and therapy of PA results in similar outcome when compared to adrenal venous sampling-based procedures.

It is of concern that the recommendations of the guidelines for a wide PA screening in approximately every second patient with arterial hypertension is not implemented in routine clinical practice. Therefore, currently the vast majority of patients suffering from PA remains undiagnosed and untreated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Funder JW et al (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:1889–1916

    Article  CAS  PubMed  Google Scholar 

  2. Hannemann A, Wallaschofski H (2012) Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies – a review of the current literature. Horm Metab Res 44:157–162

    Article  CAS  PubMed  Google Scholar 

  3. Monticone S et al (2017) Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 69:1811–1820

    Article  PubMed  Google Scholar 

  4. Milliez P et al (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243–1248

    Article  CAS  PubMed  Google Scholar 

  5. Willenberg HS (2017) How to escape from primary aldosteronism? News and views on an adrenal disorder of salt retention. Horm Metab Res 49:151–163

    Article  CAS  PubMed  Google Scholar 

  6. Williams TA et al (2017) Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5:689–699

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gomez-Sanchez E, Gomez-Sanchez CE (2014) The multifaceted mineralocorticoid receptor. Compr Physiol 4:965–994

    Article  PubMed  PubMed Central  Google Scholar 

  8. Funder JW (2017) Aldosterone and Mineralocorticoid Receptors-Physiology and Pathophysiology. Int J Mol Sci 18:E1032

    Article  PubMed  Google Scholar 

  9. Sechi LA et al (2006) Long-term renal outcomes in patients with primary aldosteronism. JAMA 295:2638–2645

    Article  CAS  PubMed  Google Scholar 

  10. Hiramatsu K et al (1981) A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 141:1589–1593

    Article  CAS  PubMed  Google Scholar 

  11. Brown MJ, Drake WM (2016) Splitting atoms: the Endocrine Society guideline for the management of primary aldosteronism. Lancet Diabetes Endocrinol 4:805–807

    Article  PubMed  Google Scholar 

  12. Funder JW (2016) Primary aldosteronism as a public health issue. Lancet Diabetes Endocrinol 4:972–973

    Article  PubMed  Google Scholar 

  13. Manolopoulou J et al (2015) Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. J Hypertens 33:2500–2511

    Article  CAS  PubMed  Google Scholar 

  14. O’Shea PM et al (2017) Screening for primary aldosteronism using the newly developed IDS-iSYS® automated assay system. Pract Lab Med 7:6–14

    Article  PubMed  Google Scholar 

  15. Pilz S et al (2009) Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. BMC Endocr Disord 9:11

    Article  PubMed  PubMed Central  Google Scholar 

  16. Amar L et al (2016) SFE/SFHTA/AFCE primary aldosteronism consensus: introduction and handbook. Ann Endocrinol (Paris) 77:179–186

    Article  Google Scholar 

  17. Stowasser M et al (2012) Factors affecting the aldosterone/renin ratio. Horm Metab Res 44:170–176

    Article  CAS  PubMed  Google Scholar 

  18. Pilz S et al (2014) Aldosterone to active renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading. Horm Metab Res 46:427–432

    Article  CAS  PubMed  Google Scholar 

  19. Tomaschitz A, Pilz S (2010) Aldosterone to renin ratio – a reliable screening tool for primary aldosteronism? Horm Metab Res 42:382–391

    Article  CAS  PubMed  Google Scholar 

  20. Fassnacht M et al (2016) Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 175:G1–G34

    Article  CAS  PubMed  Google Scholar 

  21. Dinnes J et al (2016) Management of Endocrine Disease: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol 175:R51–R64

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Mendichovszky IA et al (2016) Targeted molecular imaging in adrenal disease – an emerging role for metomidate PET-CT. Diagnostics (Basel) 6:E42

    Article  Google Scholar 

  23. Dekkers T et al (2016) Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol 4:739–746

    Article  PubMed  Google Scholar 

  24. Rossi GP et al (2017) Adrenal venous sampling versus computed tomographic scan to determine treatment in primary Aldosteronism (the SPARTACUS trial): a critique. Hypertension 69:396–397

    Article  CAS  PubMed  Google Scholar 

  25. Stowasser M, Primary Aldosteronism GRD (2016) Primary Aldosteronism GRD: Changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. Physiol Rev 96:1327–1384

    Article  PubMed  Google Scholar 

  26. Dutta RK et al (2016) Genetics of primary hyperaldosteronism. Endocr Relat Cancer 23:R437–R454

    Article  PubMed  Google Scholar 

  27. Fu B et al (2011) Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol 185:1578–1582

    Article  PubMed  Google Scholar 

  28. Steichen O et al (2016) SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: adrenal surgery. Ann Endocrinol (Paris) 77:220–225

    Article  Google Scholar 

  29. Liu SY et al (2016) Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma. Br J Surg 103:1476–1486

    Article  CAS  PubMed  Google Scholar 

  30. Mancia G et al (2013) ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013(34):2159–2219

    Google Scholar 

  31. Flatt DM et al (2016) Mineralocorticoid receptor antagonists in the management of heart failure and resistant hypertension: a review. JAMA Cardiol 1:607–612

    Article  PubMed  Google Scholar 

  32. Sechi LA et al (2015) Mineralocorticoid receptor antagonists and clinical outcomes in primary aldosteronism: as good as surgery? Horm Metab Res 47:1000–1006

    Article  CAS  PubMed  Google Scholar 

  33. Deinum J et al (2015) Pharmacological treatment of aldosterone excess. Pharmacol Ther 154:120–133

    Article  CAS  PubMed  Google Scholar 

  34. Pilz S et al (2012) Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 97:E75–E79

    Article  CAS  PubMed  Google Scholar 

  35. Pilz S et al (2010) Aldosterone and parathyroid hormone: a complex and clinically relevant relationship. Calcif Tissue Int 87:373–374

    Article  CAS  PubMed  Google Scholar 

  36. Rossi GP et al (2012) Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 60:431–436

    Article  CAS  PubMed  Google Scholar 

  37. Notsu M et al (2017) Primary aldosteronism as a risk factor for vertebral fracture. J Clin Endocrinol Metab 102:1237–1243

    Article  PubMed  Google Scholar 

  38. van Rooyen JM et al (2016) Quantification of systemic renin-angiotensin system peptides of hypertensive black and white African men established from the RAS-Fingerprint. J Renin Angiotensin Aldosterone Syst. https://doi.org/10.1177/1470320316669880

    PubMed  Google Scholar 

  39. Patel VB et al (2016) Role of the ACE2/Angiotensin 1‑7 axis of the Renin-Angiotensin system in heart failure. Circ Res 118:1313–1326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Arlt W et al (2017) Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2:93136

    Article  PubMed  Google Scholar 

  41. Asbach E et al (2016) Recent developments in primary aldosteronism. Exp Clin Endocrinol Diabetes 124:335–341

    Article  CAS  PubMed  Google Scholar 

  42. Tomaschitz A et al (2015) Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications. Clin Exp Hypertens 37:108–115

    Article  CAS  PubMed  Google Scholar 

  43. Haase M et al (2014) Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy. J Clin Endocrinol Metab 99:4397–4402

    Article  CAS  PubMed  Google Scholar 

  44. Pilz S et al. in revision (unpublished data)

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stefan Pilz PhD.

Ethics declarations

Interessenkonflikt

S. Pilz, A. Tomaschitz, C. Trummer, A. Bachmann, M. Pandis, V. Schwetz, B. Obermayer-Pietsch und W. März geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pilz, S., Tomaschitz, A., Trummer, C. et al. Primärer Hyperaldosteronismus: Diagnostik und Therapie. J. Klin. Endokrinol. Stoffw. 10, 82–91 (2017). https://doi.org/10.1007/s41969-017-0010-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41969-017-0010-7

Schlüsselwörter

Keywords

Navigation